Related Experiment Video
Updated: Jul 1, 2026

A Suction Blister Protocol to Study Human T-cell Recall Responses In Vivo
Published on: August 11, 2018
Biologics-induced cutaneous pseudolymphomas: a narrative review with an illustrative case of brodalumab-induced
Gustavo Almeida-Silva1, Inês Tribolet de Abreu1, Filipe Monteiro1
1Dermatology Department, Unidade Local de Saúde Santa Maria, Lisbon, Portugal.
Abstract:
Cutaneous pseudolymphomas (CPLs) comprise a heterogeneous group of benign lymphoid proliferations that simulate cutaneous lymphomas both clinically and histologically. Numerous causes have been identified, including infections, arthropod bites, tattoos and drugs. With the expanding use of biologic therapies for chronic inflammatory dermatoses, a growing number of drug-related CPLs have been reported. Although tumour necrosis factor inhibitors are most frequently implicated, emerging evidence suggests that other biologic therapy classes may also trigger lymphoid hyperplasia through immune dysregulation. We provide a concise narrative review of biologics-induced CPLs and illustrate the topic with the first reported case of brodalumab-induced pseudolymphoma in a patient with psoriasis. Understanding this rare adverse event is crucial for early recognition, correct histopathological interpretation and appropriate management.
Related Concept Videos
Skin Diseases and Disorders
Gram-positive Staphylococcus spp. and Streptococcus spp. are responsible for many of the most common skin infections. However, many...
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Leishmaniasis

